Cybin (OTCMKTS:CYBN) Trading Up 10.8%

Cybin Inc. (OTCMKTS:CYBNGet Free Report)’s stock price rose 10.8% during trading on Monday . The company traded as high as $0.36 and last traded at $0.36. Approximately 3,393,553 shares traded hands during mid-day trading, a decline of 12% from the average daily volume of 3,856,092 shares. The stock had previously closed at $0.32.

Cybin Stock Up 10.8 %

The firm’s 50-day moving average price is $0.39 and its two-hundred day moving average price is $0.42. The firm has a market capitalization of $146.72 million, a PE ratio of -1.98 and a beta of 0.44.

Cybin (OTCMKTS:CYBNGet Free Report) last released its earnings results on Tuesday, November 14th. The company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.05) by $0.01. Equities research analysts forecast that Cybin Inc. will post -0.19 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Belpointe Asset Management LLC lifted its stake in Cybin by 21.5% in the first quarter. Belpointe Asset Management LLC now owns 313,705 shares of the company’s stock valued at $121,000 after acquiring an additional 55,600 shares during the last quarter. Moneta Group Investment Advisors LLC lifted its stake in Cybin by 133,816.7% in the fourth quarter. Moneta Group Investment Advisors LLC now owns 66,405,251 shares of the company’s stock valued at $19,729,000 after acquiring an additional 66,355,664 shares during the last quarter. Virtu Financial LLC lifted its stake in Cybin by 104.0% in the fourth quarter. Virtu Financial LLC now owns 90,467 shares of the company’s stock valued at $27,000 after acquiring an additional 46,129 shares during the last quarter. Royal Bank of Canada lifted its stake in Cybin by 926.4% in the third quarter. Royal Bank of Canada now owns 109,239 shares of the company’s stock valued at $52,000 after acquiring an additional 98,596 shares during the last quarter. Finally, Jane Street Group LLC lifted its stake in Cybin by 370.6% in the first quarter. Jane Street Group LLC now owns 74,631 shares of the company’s stock valued at $61,000 after acquiring an additional 58,771 shares during the last quarter. 2.02% of the stock is owned by hedge funds and other institutional investors.

Cybin Company Profile

(Get Free Report)

Cybin Inc, a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation.

Further Reading

Receive News & Ratings for Cybin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cybin and related companies with MarketBeat.com's FREE daily email newsletter.